LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Inicio・Lista de Acciones・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Cerrado

SectorSanidad

3.07 0.66

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

Máximo

3.1

Métricas clave
By Trading Economics
Ingresos	4.1M -5.7M
Empleados	34
EBITDA	3.1M -6.8M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+553.59% upside

Dividendos
By Dow Jones
Próximas Ganancias	19 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-88M 300M
Apertura anterior	2.41
Cierre anterior	3.07

Noticias sobre sentimiento de mercado

By Acuity

50%

162 / 346 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

8.275 / 9.312 Soporte y Resistencia

Anavex Life Sciences Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 may 2026, 22:54 UTC

Ganancias

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 may 2026, 23:51 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

13 may 2026, 23:51 UTC

Charlas de Mercado

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 may 2026, 23:45 UTC

Charlas de Mercado

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 may 2026, 23:45 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

13 may 2026, 23:17 UTC

Ganancias

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 may 2026, 23:16 UTC

Ganancias

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 may 2026, 23:15 UTC

Ganancias

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 may 2026, 23:14 UTC

Ganancias

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 may 2026, 23:02 UTC

Charlas de Mercado

Ganancias

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 may 2026, 22:59 UTC

Charlas de Mercado

Ganancias

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 may 2026, 22:24 UTC

Ganancias

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 may 2026, 22:23 UTC

Ganancias

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 may 2026, 22:23 UTC

Ganancias

Xero FY International Revenue Growth 47%>XRO.AU

13 may 2026, 22:22 UTC

Ganancias

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 may 2026, 22:19 UTC

Ganancias

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 may 2026, 22:19 UTC

Ganancias

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 may 2026, 22:18 UTC

Ganancias

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 may 2026, 22:16 UTC

Ganancias

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 may 2026, 22:15 UTC

Ganancias

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 may 2026, 22:15 UTC

Ganancias

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 may 2026, 22:13 UTC

Ganancias

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 may 2026, 22:12 UTC

Ganancias

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 may 2026, 22:11 UTC

Ganancias

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 may 2026, 22:11 UTC

Ganancias

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 may 2026, 22:10 UTC

Ganancias

Xero Did Not Declare a Dividend>XRO.AU

13 may 2026, 22:10 UTC

Ganancias

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 may 2026, 22:09 UTC

Ganancias

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 may 2026, 22:00 UTC

Ganancias

Cisco to Shed Jobs for All-In AI Push -- Update

13 may 2026, 21:11 UTC

Ganancias

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Comparación entre iguales

Cambio de precio

Anavex Life Sciences Corp previsión

Precio Objetivo

By TipRanks

553.59% repunte

Estimación a 12 Meses

Media 20 USD 553.59%

Máximo 20 USD

Mínimo 20 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

8.275 / 9.312Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

162 / 346 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.